Human Genome Sciences (NASDAQ:HGSI)
| CAPS Rating |
|
|---|---|
| Open | $9.84 |
| Previous Close | $10.00 |
| Daily Range | $9.42 - $9.84 |
| 52-Week Range | $6.51 - $30.15 |
| Market Cap | $1.81B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 7,464,711 |
| Average Daily Volume | 0 |
HGSI
VS S&P 500 (SPY)
How do you think HGSI will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
HGSI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
HGSI News and Commentary
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Has GlaxoSmithKline Become the Perfect Stock? – The Motley Fool
- Make Money in Dynamic Biotech Stocks the Easy Way – The Motley Fool
- 6 Key Drivers for Biotechnology's 2012 Outlook – Minyanville
- 2-Star Stocks Poised to Plunge: Human Genome? – The Motley Fool
- No Vacancy: Workers Need Not Apply to This Sector – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Buy, Sell, or Hold: Human Genome Sciences – The Motley Fool
- The Magic Formula for Biotech – The Motley Fool
- A Year's Worth of Sales in 1 Month – The Motley Fool
- Biotechs Rally in Market continues.. – Blog at The Motley Fool
- Could This Stock Nearly Double 2 Years In a Row? – The Motley Fool
- Benlysta Sales Expected to Improve - Analyst Blog – NASDAQ
- Linear Growth Isn't Enough – The Motley Fool
- Regeneron Blows Away Sales Forecast for New Eye Drug – Minyanville
- Trading Plan for January 9, 2011 – Blog at The Motley Fool
- Are These Biotech Drug Launches Back on Track? – The Motley Fool
- Dendreon Investors: Why Shares Are Soaring – The Motley Fool
- 2012 Preview: K-V Pharmaceuticals – The Motley Fool
- The Worst Health-Care Stocks of 2011 – The Motley Fool
RSS Headlines
Fool UK
